Welcome!

News Feed Item

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

LONDON, April 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/non_small_cell_lung_cancer_global_clinical_trials_review.html

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014" provides data on the Non-Small Cell Lung Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Small Cell Lung Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Small Cell Lung Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Introduction 6
Non-Small Cell Lung Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Non-Small Cell Lung Cancer 25
Subjects Recruited Over a Period of Time 57
Clinical Trials by Sponsor Type 58
Prominent Sponsors 59
Top Companies Participating in Non-Small Cell Lung Cancer Therapeutics Clinical Trials 60
Prominent Drugs 62

Latest Clinical Trials News on Non-Small Cell Lung Cancer 63
Mar 02, 2014: Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer 63
Feb 19, 2014: Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival 63
Feb 17, 2014: Afatinib: added benefit depends on mutation status 64
Jan 27, 2014: Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer 65
Jan 16, 2014: ArQule Provides Updates on Clinical Trials in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer with Tivantinib 66
Clinical Trial Profiles 68
Clinical Trial Overview of Top Companies 68
F. Hoffmann-La Roche Ltd. 68
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 68
Eli Lilly and Company 84
Clinical Trial Overview of Eli Lilly and Company 84
AstraZeneca PLC 98
Clinical Trial Overview of AstraZeneca PLC 98
Pfizer Inc. 109
Clinical Trial Overview of Pfizer Inc. 109
Bristol-Myers Squibb Company 117

Clinical Trial Overview of Bristol-Myers Squibb Company 117
Sanofi 123
Clinical Trial Overview of Sanofi 123
Novartis AG 128
Clinical Trial Overview of Novartis AG 128
Merck & Co., Inc. 133
Clinical Trial Overview of Merck & Co., Inc. 133
GlaxoSmithKline plc 137
Clinical Trial Overview of GlaxoSmithKline plc 137
C. H. Boehringer Sohn AG & Co. KG 141
Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 141
Clinical Trial Overview of Top Institutes / Government 145
National Cancer Institute 145
Clinical Trial Overview of National Cancer Institute 145
The University of Texas M. D. Anderson Cancer Center 168
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 168
Memorial Sloan Kettering Cancer Center 172
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 172
West Japan Oncology Group 176
Clinical Trial Overview of West Japan Oncology Group 176
European Organization for Research and Treatment of Cancer 179
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 179
Radiation Therapy Oncology Group 182
Clinical Trial Overview of Radiation Therapy Oncology Group 182
Sun Yat-sen University 184
Clinical Trial Overview of Sun Yat-sen University 184

Eastern Cooperative Oncology Group 186
Clinical Trial Overview of Eastern Cooperative Oncology Group 186
Sarah Cannon Research Institute 188
Clinical Trial Overview of Sarah Cannon Research Institute 188
Barbara Ann Karmanos Cancer Institute 190
Clinical Trial Overview of Barbara Ann Karmanos Cancer Institute 190
Five Key Clinical Profiles 192
Appendix 292
Abbreviations 292
Definitions 292
Research Methodology 293
Secondary Research 293
About GlobalData 294
Contact Us 294
Disclaimer 294
Source 295

List of Tables

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 21

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Non-Small Cell Lung Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Non-Small Cell Lung Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 28
Non-Small Cell Lung Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 33
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 57
Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 58
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 59
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 61
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 62
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 68
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 84
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 98

Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 109
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 117
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 123
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 128
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 133
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 137
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014* 141
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 145
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 168
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 172

Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by West Japan Oncology Group, 2014* 176
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 179
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Radiation Therapy Oncology Group, 2014* 182
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sun Yat-sen University, 2014* 184
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eastern Cooperative Oncology Group, 2014* 186
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sarah Cannon Research Institute, 2014* 188
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Barbara Ann Karmanos Cancer Institute, 2014* 190

List of Figures
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17

Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 57
Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 58
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 59
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 60
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 62
GlobalData Methodology 293

Read the full report:
Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/non_small_cell_lung_cancer_global_clinical_trials_review.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The competitive landscape of the global cloud computing market in the healthcare industry is crowded due to the presence of a large number of players. The large number of participants has led to the fragmented nature of the market. Some of the major players operating in the global cloud computing market in the healthcare industry are Cisco Systems Inc., Carestream Health Inc., Carecloud Corp., AGFA Healthcare, IBM Corp., Cleardata Networks, Merge Healthcare Inc., Microsoft Corp., Intel Corp., an...
The best-practices for building IoT applications with Go Code that attendees can use to build their own IoT applications. In his session at @ThingsExpo, Indraneel Mitra, Senior Solutions Architect & Technology Evangelist at Cognizant, provided valuable information and resources for both novice and experienced developers on how to get started with IoT and Golang in a day. He also provided information on how to use Intel Arduino Kit, Go Robotics API and AWS IoT stack to build an application tha...
Is your aging software platform suffering from technical debt while the market changes and demands new solutions at a faster clip? It’s a bold move, but you might consider walking away from your core platform and starting fresh. ReadyTalk did exactly that. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, will discuss why and how ReadyTalk diverted from healthy revenue and over a decade of audio conferencing product development to start an innovati...
With an estimated 50 billion devices connected to the Internet by 2020, several industries will begin to expand their capabilities for retaining end point data at the edge to better utilize the range of data types and sheer volume of M2M data generated by the Internet of Things. In his session at @ThingsExpo, Don DeLoach, CEO and President of Infobright, discussed the infrastructures businesses will need to implement to handle this explosion of data by providing specific use cases for filterin...
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, provided tips on how to be successful in large scale machine learning...
Early adopters of IoT viewed it mainly as a different term for machine-to-machine connectivity or M2M. This is understandable since a prerequisite for any IoT solution is the ability to collect and aggregate device data, which is most often presented in a dashboard. The problem is that viewing data in a dashboard requires a human to interpret the results and take manual action, which doesn’t scale to the needs of IoT.
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...
Cloud analytics is dramatically altering business intelligence. Some businesses will capitalize on these promising new technologies and gain key insights that’ll help them gain competitive advantage. And others won’t. Whether you’re a business leader, an IT manager, or an analyst, we want to help you and the people you need to influence with a free copy of “Cloud Analytics for Dummies,” the essential guide to this explosive new space for business intelligence.
What does it look like when you have access to cloud infrastructure and platform under the same roof? Let’s talk about the different layers of Technology as a Service: who cares, what runs where, and how does it all fit together. In his session at 18th Cloud Expo, Phil Jackson, Lead Technology Evangelist at SoftLayer, an IBM company, spoke about the picture being painted by IBM Cloud and how the tools being crafted can help fill the gaps in your IT infrastructure.
"C2M is our digital transformation and IoT platform. We've had C2M on the market for almost three years now and it has a comprehensive set of functionalities that it brings to the market," explained Mahesh Ramu, Vice President, IoT Strategy and Operations at Plasma, in this SYS-CON.tv interview at @ThingsExpo, held June 7-9, 2016, at the Javits Center in New York City, NY.
"delaPlex is a software development company. We do team-based outsourcing development," explained Mark Rivers, COO and Co-founder of delaPlex Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Traditional IT, great for stable systems of record, is struggling to cope with newer, agile systems of engagement requirements coming straight from the business. In his session at 18th Cloud Expo, William Morrish, General Manager of Product Sales at Interoute, outlined ways of exploiting new architectures to enable both systems and building them to support your existing platforms, with an eye for the future. Technologies such as Docker and the hyper-convergence of computing, networking and sto...
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...
SYS-CON Events announced today that LeaseWeb USA, a cloud Infrastructure-as-a-Service (IaaS) provider, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. LeaseWeb is one of the world's largest hosting brands. The company helps customers define, develop and deploy IT infrastructure tailored to their exact business needs, by combining various kinds cloud solutions.
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, explored the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences between wh...